News

Yahoo Finance4d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Yahoo Finance
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or ...
Miami Herald4d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Miami Herald
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 8:41 AM ...
Charlotte Observer4d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Charlotte Observer
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 8:41 AM ...
The Olympian4d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | The ... - The Olympian
Updated June 24, 2025 5:21 AM Press Releases EON Resources Inc. Announces Special Conference Call Thursday, June 26,2025 at 10:30 AM EDT to Discuss Acquisition of the South Justis Field in the ...
AZ Central4d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - AZCentral | The ...
The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the ...